Silk Road Medical has announced the appointment of Michael P Wallace to the position of chief technology officer. In this new role, Wallace will lead the company’s Research and Development efforts across its family of transcarotid access and treatment devices.
Prior to joining Silk Road Medical, Wallace was the vice president of Research and Development at Boston Scientific’s Electrophysiology Division and previously held senior technical leadership roles at Baxano Surgical, BARRx Medical, and Boston Scientific Neurovascular / Target Therapeutics. He has over 20 years of experience in the medical device field and holds over 120 issued or pending US patents.
“The addition of Mike Wallace completes the all-star executive line up at Silk Road. Our executives are deeply experienced in the fields of carotid and neurovascular diseases and are considered the best in the industry across marketing, clinical, operations, and R&D. Our impressive executive team and the recently announced completion of enrolment in our pivotal ROADSTER trial positions Silk Road Medical for the promising future of transcarotid interventions,” says Erica Rogers, president and chief executive officer.
“I am thrilled to join Silk Road to lead the R&D team through the commercial development of its pioneering and unique Enroute transcarotid neuroprotection and stent systems for treating blockages in the artery of the neck. Despite decades of development, traditional transfemoral carotid stenting (CAS) has been associated with an excess risk of stroke due to aortic arch catheterisation and less than ideal embolic protection devices. With Silk Road’s surgically-inspired approach, we believe we can reduce the risk of stroke on par with the gold standard of carotid endarterectomy (CEA) while preserving the benefits of a less invasive stenting procedure,” says Wallace. “Looking forward, I am also equally excited about the opportunity to help patients with neurovascular diseases by developing a suite of products that highlights the surgeon control and procedure time advantages we believe are possible with our transcarotid access point.”
